Literature DB >> 9402971

Genotype-phenotype correlation in cystic fibrosis patients compound heterozygous for the A455E mutation.

M De Braekeleer1, C Allard, J P Leblanc, F Simard, G Aubin.   

Abstract

Cystic fibrosis (CF) has a high incidence in the French-Canadian population of Saguenay Lac-Saint-Jean (Quebec). The A455E mutation accounts for 8.3% of the CF chromosomes. This mutation was shown to be associated with a milder lung disease in the Dutch population. Twenty two CF patients distributed in 17 families and compound heterozygotes for the A455E mutation have been followed at the Clinique de Fibrose Kystique de Chicoutimi. Fourteen patients also carried the delta F508 mutation while the remaining eight patients had the 621 + 1G-->T mutation. Each patient was matched by sex and age to a patient homozygous for the delta F508 mutation. The pairs were analyzed for several clinical and laboratory variables. The A455E compound heterozygotes were diagnosed at a later age (P = 0.003) and had chloride concentrations at the sweat test lower than those homozygous for the delta F508 mutation (P = 0.007). More patients were pancreatic sufficient (P = 0.004). They had a higher Shwachman score (P = 0.001) and better pulmonary function tests (P < 0.02). CF patients compound heterozygous for the A455E mutation have a milder pancreatic and lung disease than the delta F508 homozygotes. Therefore, the A455E should be associated with a better prognosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9402971     DOI: 10.1007/s004390050616

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  9 in total

1.  A gene-based recessive diplotype exome scan discovers FGF6, a novel hepcidin-regulating iron-metabolism gene.

Authors:  Shicheng Guo; Shuai Jiang; Narendranath Epperla; Yanyun Ma; Mehdi Maadooliat; Zhan Ye; Brent Olson; Minghua Wang; Terrie Kitchner; Jeffrey Joyce; Peng An; Fudi Wang; Robert Strenn; Joseph J Mazza; Jennifer K Meece; Wenyu Wu; Li Jin; Judith A Smith; Jiucun Wang; Steven J Schrodi
Journal:  Blood       Date:  2019-02-27       Impact factor: 22.113

Review 2.  Modifier genes in Mendelian disorders: the example of cystic fibrosis.

Authors:  Garry R Cutting
Journal:  Ann N Y Acad Sci       Date:  2010-12       Impact factor: 5.691

3.  Atypical presentation of cystic fibrosis at 70 years of age.

Authors:  Muhammad Adnan Saleem; Aled Phillips; Muhammad Badar Ganaie
Journal:  BMJ Case Rep       Date:  2019-06-03

4.  Genetic determinants of Pseudomonas aeruginosa colonization in cystic fibrosis patients in Canada.

Authors:  M De Braekeleer; C Allard; J P Leblanc; G Aubin; F Simard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

5.  Assessing the Disease-Liability of Mutations in CFTR.

Authors:  Claude Ferec; Garry R Cutting
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

6.  Role of oxygen availability in CFTR expression and function.

Authors:  Jennifer S Guimbellot; James A Fortenberry; Gene P Siegal; Bryan Moore; Hui Wen; Charles Venglarik; Yiu-Fai Chen; Suzanne Oparil; Eric J Sorscher; Jeong S Hong
Journal:  Am J Respir Cell Mol Biol       Date:  2008-05-12       Impact factor: 6.914

7.  Correcting the cystic fibrosis disease mutant, A455E CFTR.

Authors:  Liudmila Cebotaru; Daniele Rapino; Valeriu Cebotaru; William B Guggino
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

8.  Spectrum of CFTR gene mutations in Ecuadorian cystic fibrosis patients: the second report of the p.H609R mutation.

Authors:  Sofía C Ortiz; Santiago J Aguirre; Sofía Flores; Claudio Maldonado; Juan Mejía; Lilian Salinas
Journal:  Mol Genet Genomic Med       Date:  2017-10-11       Impact factor: 2.183

Review 9.  Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders.

Authors:  Samuel M Moskowitz; James F Chmiel; Darci L Sternen; Edith Cheng; Ronald L Gibson; Susan G Marshall; Garry R Cutting
Journal:  Genet Med       Date:  2008-12       Impact factor: 8.822

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.